Orofacial Therapeutics, LP – Trademark Portfolio

Entity Type: 13

Orofacial Therapeutics, LP holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SPEED2TREAT. The owner is based in San Diego, CA.

6824 El Cajon Blvd.

San Diego, CA 92115

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Orofacial Therapeutics, LP's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Orofacial Therapeutics, LP have?

Orofacial Therapeutics, LP has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.

What trademark classes does Orofacial Therapeutics, LP file in?

Orofacial Therapeutics, LP files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Orofacial Therapeutics, LP's most well-known trademarks?

Orofacial Therapeutics, LP's registered trademark portfolio includes well-known marks such as SPEED2TREAT. These are among 1 currently registered trademark in the portfolio.

What is Orofacial Therapeutics, LP's trademark registration success rate?

Orofacial Therapeutics, LP has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.